- Public Comps
- Bluejay Diagnostics
Bluejay Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bluejay Diagnostics and similar public comparables like Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva and more.
Bluejay Diagnostics Overview
About Bluejay Diagnostics
Bluejay Diagnostics Inc is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ‘sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions.
Founded
2015
HQ

Employees
7
Website
Financials (FY)
Market Cap
$1M
Valuation Multiples
Start free trialBluejay Diagnostics Financials
Bluejay Diagnostics reported last fiscal year revenue of - and negative EBITDA of ($7M).
In the same fiscal year, Bluejay Diagnostics generated ($7M) in EBITDA losses and had net loss of ($7M).
Bluejay Diagnostics P&L
In the most recent fiscal year, Bluejay Diagnostics reported revenue of - and EBITDA of ($7M).
Bluejay Diagnostics is unprofitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Bluejay Diagnostics Stock Performance
Bluejay Diagnostics has current market cap of $1M.
Bluejay Diagnostics' stock price is $1.06.
Bluejay Diagnostics has an EPS (earnings per share) of $-6.62.
| Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|
| $1M | 1.0% | - | - | - | $-6.62 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBluejay Diagnostics Valuation Multiples
Bluejay Diagnostics trades at 0.4x EV/EBITDA.
Bluejay Diagnostics Financial Valuation Multiples
As of August 14, 2026, Bluejay Diagnostics has market cap of $1M.
Bluejay Diagnostics has a P/E ratio of (0.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bluejay Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Bluejay Diagnostics Margins & Growth Rates
Bluejay Diagnostics Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Bluejay Diagnostics Operational KPIs
Bluejay Diagnostics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.0M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Bluejay Diagnostics Competitors
Bluejay Diagnostics competitors include Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva, Bone Biologics, Luxbright, Brain Scientific, Integragen, Inhalation Sciences SWE and EvokAI.
Most Bluejay Diagnostics public comparables operate across Diagnostics & Genomics, Medical Devices, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 499.8x | - | (38.2x) | - | |||
| - | - | - | - | |||
| - | - | (2.2x) | - | |||
| - | - | - | - | |||
| - | - | 1.0x | - | |||
| 0.8x | 0.8x | (0.6x) | (0.5x) | |||
| 14.2x | - | (0.4x) | - | |||
| 0.0x | - | (2.6x) | - | |||
This data is available for Pro users. Sign up to see all Bluejay Diagnostics competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bluejay Diagnostics
| When was Bluejay Diagnostics founded? | Bluejay Diagnostics was founded in 2015. |
| Where is Bluejay Diagnostics headquartered? | Bluejay Diagnostics is headquartered in United States. |
| How many employees does Bluejay Diagnostics have? | As of today, Bluejay Diagnostics has over 7 employees. |
| Is Bluejay Diagnostics publicly listed? | Yes, Bluejay Diagnostics is a public company listed on Nasdaq. |
| What is the stock symbol of Bluejay Diagnostics? | Bluejay Diagnostics trades under BJDX ticker. |
| When did Bluejay Diagnostics go public? | Bluejay Diagnostics went public in 2021. |
| Who are competitors of Bluejay Diagnostics? | Bluejay Diagnostics main competitors include Epigenomics, Biora Therapeutics, Odyssey Health, Sunniva, Bone Biologics, Luxbright, Brain Scientific, Integragen, Inhalation Sciences SWE, EvokAI. |
| What is the current market cap of Bluejay Diagnostics? | Bluejay Diagnostics' current market cap is $1M. |
| Is Bluejay Diagnostics profitable? | No, Bluejay Diagnostics is not profitable. |
| How many companies Bluejay Diagnostics has acquired to date? | Bluejay Diagnostics hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Bluejay Diagnostics has invested to date? | Bluejay Diagnostics hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Bluejay Diagnostics
Lists including Bluejay Diagnostics
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




